Results 31 to 40 of about 110,790 (277)

Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates.

open access: yesPLoS ONE, 2022
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease caused by uncontrolled complement activation; effective and approved treatments include terminal complement inhibition.
Kishor Devalaraja-Narashimha   +7 more
doaj   +2 more sources

Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models

open access: yesFrontiers in Immunology, 2018
Complement is essential for the protection against infections; however, dysregulation of complement activation can cause onset and progression of numerous inflammatory diseases.
Seline A. Zwarthoff   +8 more
doaj   +1 more source

Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice [PDF]

open access: yes, 2014
Sepsis and septic shock, caused by an excessive systemic host-inflammatory response, are associated with high morbidity and mortality. The complement system and TLRs provide important pattern recognition receptors initiating the cytokine storm by ...
Barratt-Due, Andreas   +9 more
core   +1 more source

Complement system activation contributes to the ependymal damage induced by microbial neuraminidase [PDF]

open access: yes, 2016
Background In the rat brain, a single intracerebroventricular injection of neuraminidase from Clostridium perfringens induces ependymal detachment and death.
A Ascherio   +84 more
core   +2 more sources

White matter injury due to experimental chronic cerebral hypoperfusion is associated with C5 deposition. [PDF]

open access: yesPLoS ONE, 2013
The C5 complement protein is a potent inflammatory mediator that has been implicated in the pathogenesis of both stroke and neurodegenerative disease. Microvascular failure is proposed as a potential mechanism of injury.
Qinghai Liu   +7 more
doaj   +1 more source

Sublytic Terminal Complement Components Induce Eryptosis in Autoimmune Haemolytic Anaemia Related to IgM Autoantibodies [PDF]

open access: yes, 2019
BACKGROUND/AIMS: Eryptosis, the suicidal death of red blood cells (RBCs), is characterized by phosphatidylserine (PS) exposure at the cell surface. It can be catalysed by a variety of abnormal conditions and diseases.
Balola, Abdelwahab Hassan Ahmed   +3 more
core   +1 more source

A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug intervention. [PDF]

open access: yesPLoS ONE, 2018
The complement system is an intricate defense network that rapidly removes invading pathogens. Although many complement regulators are present to protect host cells under homeostasis, the impairment of Factor H (FH) regulatory mechanism has been ...
Nehemiah Zewde, Dimitrios Morikis
doaj   +1 more source

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases

open access: yesScientific Reports, 2017
Dysregulation of the complement system is linked to the pathogenesis of a variety of hematological disorders. Eculizumab, an anti-complement C5 monoclonal antibody, is the current standard of care for paroxysmal nocturnal hemoglobinuria (PNH) and ...
Taku Fukuzawa   +33 more
doaj   +1 more source

Complement Split Product C5a Mediates the Lipopolysaccharide‐Induced Mobilization of Cfu‐S and Haemopoietic Progenitor Cells, But Not the Mobilization Induced By Proteolytic Enzymes [PDF]

open access: yes, 1986
. Intravenous (i.v.) injection of mice with lipopolysaccharide (LPS), and the proteolytic enzymes trypsin and proteinase, mobilizes pluripotent haemopoietic stem cells (CFU‐s) as well as granulocyte‐macrophage progenitor cells (GM‐CFU) and the early ...
Benner R.   +25 more
core   +1 more source

Inhibitors of C5 complement enhance vaccinia virus oncolysis [PDF]

open access: yesCancer Gene Therapy, 2013
Genetically engineered tumor-selective vaccinia virus (VV) has been demonstrated to be a highly effective oncolytic agent, but immune clearance may limit its therapeutic potential. As previously demonstrated, immunosuppression can lead to significant enhancement of viral recovery and therapeutic effect, but the magnitude of complement-mediated viral ...
D, Magge   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy